Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 258

The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.

EULAR recommendations for the treatment of systemic sclerosis: 2023 update

Open access
Del Galdo, Francesco, Lescoat, Alain, Conaghan, Philip G., Bertoldo, Eugenia, Čolić, Jelena, Santiago, Tânia, Suliman, Yossra A., Matucci-Cerinic, Marco, Gabrielli, Armando, Distler, Oliver, Hoffmann-Vold, Anna-Maria, Castellví, Ivan, Balbir-Gurman, Alexandra, Vonk, Madelon, Ananyeva, Lidia, Rednic, Simona, Tarasova, Anna, Ostojic, Pedrag, Boyadzhieva, Vladimira, El Aoufy, Khadija, Farrington, Sue, Galetti, Ilaria, Denton, Christopher P., Kowal-Bielecka, Otylia, Mueller-Ladner, Ulf, Allanore, Yannick·2025·Annals of the Rheumatic Diseases

Abstract

OBJECTIVES: To update the 2017 European Alliance of Associations for Rheumatology (EULAR) recommendations for treatment of systemic sclerosis (SSc), incorporating new evidence and therapies. METHODS: An international task force was convened in line with EULAR standard operating procedures. A nominal group technique exercise was performed in two rounds to define questions underpinning a subsequent systematic literature review. The evidence derived was discussed and overarching principles, recommendations and future research agenda were iteratively developed with voting rounds. RESULTS: The task force agreed on 22 recommendations covering 8 clinical/organ domains including Raynaud's phenomenon, digital ulcers, pulmonary arterial hypertension, scleroderma renal crisis, skin fibrosis, interstitial lung disease (ILD), gastrointestinal manifestations and arthritis. Most new recommendations are related to skin fibrosis and ILD. These included novel recommendations for the use of mycophenolate mofetil, nintedanib, rituximab and tocilizumab for the treatment of these crucial disease manifestations. The recommendations also included first-line and second-line interventions, providing increased utility for rheumatology practitioners. Important additions to the future research agenda included consideration of novel interventions for the management of vascular, musculoskeletal and gastrointestinal manifestations and calcinosis, as well as for the local management of digital ulcers. CONCLUSION: These updated recommendations include the first set of synthetic and biological targeted therapies recommended for key fibrotic manifestations of SSc as well as first-line combination treatment for newly diagnosed pulmonary artery hypertension and prioritise a new research agenda for the coming years.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/ard-2024-226430

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 52 references

Metadata

Authors
Del Galdo, F., Lescoat, A., Conaghan, P. G., Bertoldo, E., Čolić, J., Santiago, T., Suliman, Y. A., Matucci-Cerinic, M., Gabrielli, A., Distler, O., Hoffmann-Vold, A.-M., Castellví, I., Balbir-Gurman, A., Vonk, M., Ananyeva, L., Rednic, S., Tarasova, A., Ostojic, P., Boyadzhieva, V., El Aoufy, K., Farrington, S., Galetti, I., Denton, C. P., Kowal-Bielecka, O., Mueller-Ladner, U., & Allanore, Y.
Venue
Annals of the Rheumatic Diseases
Publisher
Elsevier BV
Published
2025-01
Volume
84
Issue
1
Pages
29-40
ISSN
0003-4967 (ISSN-L)
OpenAlex
W4403331150
Cited by
258
References
52
FWCI
67.61
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: EULAR recommendations for the treatment of systemic sclerosis: 2023 update. https://app.cochat.ai/papers/10.1136/ard-2024-226430
The paper
Del Galdo, F., Lescoat, A., Conaghan, P. G., Bertoldo, E., Čolić, J., Santiago, T., Suliman, Y. A., Matucci-Cerinic, M., Gabrielli, A., Distler, O., Hoffmann-Vold, A.-M., Castellví, I., Balbir-Gurman, A., Vonk, M., Ananyeva, L., Rednic, S., Tarasova, A., Ostojic, P., Boyadzhieva, V., . . . Allanore, Y. (2025). EULAR recommendations for the treatment of systemic sclerosis: 2023 update. Annals of the Rheumatic Diseases. https://doi.org/10.1136/ard-2024-226430

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.